117 related articles for article (PubMed ID: 7660886)
1. The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor.
Jackman AL; Kimbell R; Brown M; Brunton L; Harrap KR; Wardleworth JM; Boyle FT
Adv Exp Med Biol; 1994; 370():185-8. PubMed ID: 7660886
[No Abstract] [Full Text] [Related]
2. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
3. Substituted-2-desamino-2-methyl-quinazolinones. A series of novel antitumour agents.
Boyle FT; Matusiak ZS; Hughes LR; Slater AM; Stephens TC; Smith MN; Brown M; Kimbell R; Jackman AL
Adv Exp Med Biol; 1993; 338():585-8. PubMed ID: 8304185
[No Abstract] [Full Text] [Related]
4. The duration of the inhibition of thymidylate synthase in intact L1210 cells exposed to two different classes of quinazoline analogues.
Kimbell R; Jackman AL; Boyle FT; Hardcastle A; Aherne W
Adv Exp Med Biol; 1993; 338():597-600. PubMed ID: 8304189
[No Abstract] [Full Text] [Related]
5. Biochemical and antitumor effects of 5,8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase.
Fernandes DJ; Bertino JR; Hynes JB
Cancer Res; 1983 Mar; 43(3):1117-23. PubMed ID: 6825083
[No Abstract] [Full Text] [Related]
6. A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.
Jones TR; Calvert AH; Jackman AL; Brown SJ; Jones M; Harrap KR
Eur J Cancer (1965); 1981 Jan; 17(1):11-9. PubMed ID: 7262141
[No Abstract] [Full Text] [Related]
7. Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor.
Kobayashi H; Takemura Y; Miyachi H
Cancer Chemother Pharmacol; 1998; 42(2):105-10. PubMed ID: 9654109
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
9. Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.
Harrap KR
Cancer Res; 1995 Jul; 55(13):2761-8. PubMed ID: 7796401
[TBL] [Abstract][Full Text] [Related]
10. Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors.
Stephens TC; Smith MN; Waterman SE; McCloskey ML; Jackman AL; Boyle FT
Adv Exp Med Biol; 1993; 338():589-92. PubMed ID: 8304186
[No Abstract] [Full Text] [Related]
11. Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance.
Calvert AH; Jones TR; Dady PJ; Grzelakowska-Sztabert B; Paine RM; Taylor GA; Harrap KR
Eur J Cancer (1965); 1980 May; 16(5):713-22. PubMed ID: 7389797
[No Abstract] [Full Text] [Related]
12. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors.
Marsham PR; Wardleworth JM; Boyle FT; Hennequin LF; Kimbell R; Brown M; Jackman AL
J Med Chem; 1999 Sep; 42(19):3809-20. PubMed ID: 10508430
[TBL] [Abstract][Full Text] [Related]
14. ZD-9331 AstraZeneca.
Niculescu-Duvaz I
Curr Opin Investig Drugs; 2000 Sep; 1(1):141-9. PubMed ID: 11249590
[TBL] [Abstract][Full Text] [Related]
15. Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8- dideazafolate as antitumour agents.
Jackman AL; Bisset GM; Jodrell DI; Gibson W; Kimbell R; Bavetsias V; Calvert AH; Harrap KR; Stephens TC; Smith MN
Adv Exp Med Biol; 1993; 338():579-84. PubMed ID: 8304184
[TBL] [Abstract][Full Text] [Related]
16. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.
Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT
Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479
[TBL] [Abstract][Full Text] [Related]
17. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.
Duch DS; Banks S; Dev IK; Dickerson SH; Ferone R; Heath LS; Humphreys J; Knick V; Pendergast W; Singer S
Cancer Res; 1993 Feb; 53(4):810-8. PubMed ID: 8428362
[TBL] [Abstract][Full Text] [Related]
18. Quinazoline antifolates inhibiting thymidylate synthase: synthesis of gamma-linked peptide and amide analogues of 2-desamino-2-methyl-N10-propargyl- 5,8-dideazafolic acid (ICI 198583).
Bavetsias V; Jackman AL; Thornton TJ; Pawelczak K; Boyle FT; Bisset GM
Adv Exp Med Biol; 1993; 338():593-6. PubMed ID: 8304188
[No Abstract] [Full Text] [Related]
19. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
[TBL] [Abstract][Full Text] [Related]
20. Quinazoline antifolates inhibiting thymidylate synthase: computer modelling of the N10 substituent.
Jones TR; Betteridge RF; Neidle S; Jackman AL; Calvert AH
Anticancer Drug Des; 1989 Mar; 3(4):243-8. PubMed ID: 2930626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
